Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.77 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4428858 | 0.94 | USP30 (0.72) | USP30BACE1BACE2DGAT1AAK1 | |
| SCHEMBL12715428 | 0.90 | USP30 (0.73) | USP30BACE1BACE2DGAT1AAK1 | |
| SCHEMBL124363 | 0.87 | USP30 (1.00) | USP30BACE1BACE2DGAT1AAK1 | |
| SCHEMBL16526167 | 0.85 | USP30 (0.67) | USP30BACE1BACE2DGAT1AAK1 | |
| SCHEMBL31093315 | 0.81 | USP30 (0.61) | USP30BACE1BACE2DGAT1AAK1 | |
| SCHEMBL17643639 | 0.79 | USP30 (0.59) | USP30BACE1BACE2DGAT1AAK1 | |
| SCHEMBL442120 | 0.78 | USP30 (0.58) | USP30DGAT1FFAR1 | |
| SCHEMBL799138 | 0.76 | USP30 (0.53) | USP30BACE1BACE2DGAT1AAK1 | |
| SCHEMBL152977 | 0.76 | USP30 (0.56) | USP30DGAT1FFAR1 | |
| SCHEMBL28458171 | 0.76 | USP30 (0.56) | USP30DGAT1AAK1PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410128-B2 | Triazolopyridine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-02 | — | — | US | disclosed |
| US-20110288085-A1 | IMIDAZOPYRIDINE AND IMIDAZOPYRAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-24 | — | — | US | disclosed |
| EP-2307411-A1 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-04-13 | — | — | EP | disclosed |
| US-20110077243-A1 | Triazolopyridine Compounds Useful As Kinase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-03-31 | — | — | US | disclosed |
| EP-2300466-A1 | IMIDAZOPYRIDINE AND IMIDAZOPYRAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077243-A1 | Triazolopyridine Compounds Useful As Kinase Inhibitors | MAP3K1, MAP3K5, MAP3K8 | USP30 4162/4885BACE1 3492/4885BACE2 3605/4885 |
| US-20110288085-A1 | IMIDAZOPYRIDINE AND IMIDAZOPYRAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | MAP4K2, MAPKAPK2, MAP3K5 | USP30 3219/4885BACE1 4191/4885BACE2 4240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.